AMLODIPINE BESYLATE AND VALSARTAN Drug Patent Profile

When do Amlodipine Besylate And Valsartan patents expire, and what generic alternatives are available?

Amlodipine Besylate And Valsartan is a drug marketed by Alembic, Aurobindo Pharma, Hetero Labs, Lupin, Macleods Pharms, Mylan, Novel Labs Inc, Strides Pharma Intl, Teva Pharms Usa, and Torrent. and is included in ten NDAs.

The generic ingredient in AMLODIPINE BESYLATE AND VALSARTAN is amlodipine besylate; valsartan. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the amlodipine besylate; valsartan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amlodipine Besylate And Valsartan

A generic version of AMLODIPINE BESYLATE AND VALSARTAN was approved as amlodipine besylate; valsartan by STRIDES PHARMA INTL on March 28^th, 2013.

Summary for AMLODIPINE BESYLATE AND VALSARTAN

US Patents:	0
Applicants:	10
NDAs:	10
Finished Product Suppliers / Packagers:	8
Clinical Trials:	3
DailyMed Link:	AMLODIPINE BESYLATE AND VALSARTAN at DailyMed

Recent Clinical Trials for AMLODIPINE BESYLATE AND VALSARTAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Haining Health-Coming Biotech Co., Ltd.	Phase 2
Alphacait, LLC	Phase 2
CJ HealthCare Corporation	Phase 1

See all AMLODIPINE BESYLATE AND VALSARTAN clinical trials

Pharmacology for AMLODIPINE BESYLATE AND VALSARTAN

Drug Class	Angiotensin 2 Receptor Blocker Calcium Channel Blocker Dihydropyridine Calcium Channel Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists Calcium Channel Antagonists Cytochrome P450 3A Inhibitors

US Patents and Regulatory Information for AMLODIPINE BESYLATE AND VALSARTAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma Intl	AMLODIPINE BESYLATE AND VALSARTAN	amlodipine besylate; valsartan	TABLET;ORAL	090011-004	Mar 28, 2013	AB	RX	No	No
Novel Labs Inc	AMLODIPINE BESYLATE AND VALSARTAN	amlodipine besylate; valsartan	TABLET;ORAL	202829-004	Mar 30, 2015	AB	RX	No	No
Teva Pharms Usa	AMLODIPINE BESYLATE AND VALSARTAN	amlodipine besylate; valsartan	TABLET;ORAL	091235-001	Mar 30, 2015		DISCN	No	No

Amlodipine Besylate and Valsartan Market Dynamics and Financial Trajectory

Last updated: August 14, 2026

Amlodipine besylate and valsartan is a mature fixed-dose combination for hypertension. The original branded product, Exforge, was developed by Novartis and approved by the FDA in 2007. Its commercial protection has largely expired, leaving a multi-source generic market with substantial price competition. Financial value has shifted from branded product sales to high-volume, low-margin generic prescriptions, hospital tenders, and combination-therapy substitution.

The product remains commercially relevant because hypertension is a large chronic market, fixed-dose combinations improve treatment persistence, and both active ingredients are widely prescribed. Revenue growth is constrained by generic erosion, therapeutic substitution, payer pressure, and competition from other angiotensin-receptor blocker and calcium-channel blocker combinations.

What is amlodipine besylate and valsartan?

Amlodipine besylate and valsartan combines two antihypertensive mechanisms:

• Amlodipine is a dihydropyridine calcium-channel blocker.
• Valsartan is an angiotensin II receptor blocker, or ARB.
• The combination reduces blood pressure through complementary vascular and renin-angiotensin system effects.

The FDA-approved strengths for Exforge included:

Amlodipine	Valsartan
5 mg	160 mg
10 mg	160 mg
5 mg	320 mg
10 mg	320 mg

The product is administered once daily. It is generally used when blood pressure is not adequately controlled with monotherapy or when a patient is already receiving both components separately. The FDA approved Exforge for adults with hypertension and as initial therapy in selected patients requiring multiple drugs for blood-pressure control (U.S. Food and Drug Administration [FDA], 2007).

What is the FDA regulatory status of amlodipine and valsartan?

The original U.S. product is Exforge, approved under NDA 021984. The product is no longer protected by meaningful brand exclusivity in the United States, and generic amlodipine besylate and valsartan tablets are approved through ANDAs.

Regulatory item	Status
Reference product	Exforge
Original sponsor	Novartis Pharmaceuticals
FDA approval	2007
Dosage form	Immediate-release oral tablet
Route	Oral
FDA pathway for generics	ANDA
Current market structure	Multi-source generic
Biosimilar pathway	Not applicable
Pediatric exclusivity	No current commercial significance
Therapeutic category	Antihypertensive combination

Generic approval requires pharmaceutical equivalence and bioequivalence to the reference product. Because the product is a small-molecule tablet, manufacturers do not face the comparability and interchangeability requirements associated with biologics or biosimilars.

What patents protect amlodipine besylate and valsartan?

The principal original U.S. patent estate covered the combination composition and related pharmaceutical formulations. Public patent records identify U.S. Patent No. 6,485,745 as a central patent associated with the amlodipine and valsartan combination. The patent was assigned to Novartis-related entities and claimed pharmaceutical compositions containing the two active ingredients.

The relevant patent position is now commercially weak because the principal composition and formulation protection expired or reached the end of its effective term before the current generic market matured. Later patents and regulatory listings may have covered specific formulations, dosing arrangements, or related products, but those rights did not preserve broad exclusivity for the immediate-release combination.

IP category	Commercial effect
Combination composition	Historical protection; no longer blocks ordinary generic entry
Immediate-release tablet formulation	Historical protection; largely expired
Dosing and method-of-use claims	Limited scope after generic launch
Combination with hydrochlorothiazide	Separate product and patent analysis
Salt and polymorph claims	Potentially relevant only if specifically listed and enforceable
Manufacturing process claims	May affect selected suppliers but generally do not prevent ANDA entry
Trade dress and brand claims	Do not create pharmaceutical exclusivity

Patent status must be evaluated by jurisdiction and claim scope. A patent covering a manufacturing process does not necessarily prevent a competitor from marketing a product made by a non-infringing process. Similarly, a method-of-use patent may not block a label that omits the patented use.

When did amlodipine and valsartan lose exclusivity?

The product lost practical U.S. exclusivity when ANDA applicants were able to enter after resolution or expiration of the relevant Orange Book-listed barriers. Generic competition followed the end of the original Exforge protection period, and the product is now a mature multisource medicine.

The commercial timeline is:

Period	Market event	Financial impact
2007	FDA approves Exforge	Launch of premium branded combination
2008-2012	Brand expansion and broader physician adoption	Growth in branded sales
Early 2010s	ANDA development and Paragraph IV activity	Rising erosion risk
Mid-2010s	Generic products reach the U.S. market	Sharp price and share pressure
Late 2010s	Broad generic availability	Brand value declines materially
2020s	Mature generic market	Volume remains, unit economics compress

Novartis reported Exforge as part of its cardiovascular portfolio during the period when the product had branded exclusivity. After generic entry, Exforge became a minor commercial asset relative to newer medicines and was no longer a major growth driver for the company (Novartis, annual reports).

What is the Orange Book status of Exforge?

Exforge is the reference listed drug for amlodipine besylate and valsartan tablets. The Orange Book historically listed patents associated with the product, but those listings no longer provide a practical barrier to ordinary generic substitution.

A current Orange Book review should distinguish among:

1. Patents listed against the reference product.
2. The expiration date of each listed patent.
3. Whether pediatric extensions apply.
4. Whether a listed patent covers the marketed dosage form.
5. Whether an ANDA applicant certified under Paragraph IV.
6. Whether litigation created a 30-month stay.
7. Whether the generic label includes or omits a patented indication.

The original product is not comparable to a protected biologic with continuing interchangeability disputes. It is a conventional small-molecule combination with established generic competition.

Which companies are challenging Exforge?

The market has been challenged primarily by generic manufacturers rather than by a single high-profile innovator-to-innovator competitor. U.S. and international generic suppliers have competed through ANDA filings, national approvals, hospital contracts, pharmacy benefit channels, and private-label distribution.

Relevant supplier groups include:

• Large U.S. generic manufacturers.
• European generic companies.
• Indian pharmaceutical manufacturers.
• Contract manufacturers supplying regional brands.
• Pharmacy and wholesaler private-label programs.

The exact competitive set varies by country because marketing authorizations, supply contracts, reimbursement rules, and substitution practices differ. A supplier may hold FDA approval without achieving meaningful commercial share if it lacks wholesaler access, stable active pharmaceutical ingredient supply, or payer coverage.

What Paragraph IV challenges affected amlodipine and valsartan?

Paragraph IV certification is the principal U.S. mechanism for challenging an unexpired Orange Book patent during ANDA review. A generic applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed.

For Exforge, Paragraph IV activity was commercially relevant before generic entry because it could accelerate market access and trigger patent litigation. A first-filer could potentially obtain 180-day generic exclusivity under the applicable Hatch-Waxman framework, although the commercial value of that exclusivity depends on litigation outcomes, forfeiture rules, co-first-filer status, and launch timing.

The relevant business conclusion is that Paragraph IV risk has passed from a launch-enabling event to a historical litigation issue. Current entrants generally compete in a post-exclusivity market rather than seeking to unlock the first generic position.

What formulations are protected by amlodipine and valsartan patents?

The commercially important dosage form is the immediate-release tablet. Formulation protection historically focused on combining amlodipine and valsartan in a stable oral pharmaceutical composition.

Potential formulation issues include:

• Uniform distribution of both active ingredients.
• Stability under long-term storage.
• Control of tablet dissolution.
• Selection of excipients.
• Moisture protection.
• Manufacturing compression parameters.
• Dose proportionality across strengths.

These issues can create manufacturing barriers without creating durable market exclusivity. A generic company that uses different excipients or a different manufacturing process may avoid a formulation claim while still meeting bioequivalence requirements.

Exforge HCT, which combines amlodipine, valsartan, and hydrochlorothiazide, is a separate product. Its patent and generic-entry analysis should not be merged with the two-drug combination.

How strong is the patent estate for amlodipine and valsartan?

The current patent estate is weak from a blocking perspective and moderate only for narrow technical claims.

Patent-strength factor	Assessment
Broad composition claims	Expired or commercially exhausted
Active Orange Book barrier	Low
Method-of-use protection	Limited by label design and expiration
Formulation claims	Narrow and potentially design-aroundable
Manufacturing claims	Relevant to individual suppliers, not usually market-wide
Brand protection	Exforge name remains distinct, but does not prevent generic substitution
Biosimilar barrier	None
Litigation leverage	Low for ordinary generic entry

The strongest remaining practical barriers are operational rather than patent-based: reliable API sourcing, regulatory compliance, product quality, launch economics, and pharmacy-channel access.

How does amlodipine and valsartan compare with competing antihypertensive combinations?

Amlodipine and valsartan competes with other fixed-dose ARB/calcium-channel blocker products and with the separate use of generic components.

Product or regimen	Competitive position
Amlodipine/valsartan	Established ARB/CCB combination with broad generic availability
Amlodipine/olmesartan	Strong branded and generic alternative
Amlodipine/telmisartan	Alternative ARB/CCB combination, often positioned around longer half-life
Amlodipine/losartan	Lower-cost alternative in some markets
Valsartan alone plus amlodipine alone	Flexible dosing, often lower acquisition cost
ARB/thiazide combinations	Compete where volume control and guideline sequencing favor diuretics
ACE inhibitor/CCB combinations	Alternative class combination, subject to tolerability and prescribing preference

The two-drug combination has an adherence advantage over two separate tablets. That advantage is weakened when insurers price the individual generic components below the fixed-dose tablet or when prescribers need independent dose titration.

What is the financial trajectory of amlodipine and valsartan?

The financial trajectory follows the standard lifecycle of a successful small-molecule combination:

1. Branded expansion. Exforge generated meaningful revenue during the period of patent and market exclusivity.
2. Pre-generic erosion. Anticipated ANDA filings reduced long-term valuation and pressured prescribing.
3. Generic entry. Prices fell sharply as multiple manufacturers entered.
4. Mature generic volume. Prescription demand persisted, but gross margins and manufacturer revenue per tablet declined.
5. Stable low-growth phase. Commercial value depends on supply reliability, contracting, and manufacturing cost.

Product-level revenue is no longer separately disclosed in a way that supports a reliable current global estimate. Novartis financial reporting aggregates or de-emphasizes mature products, while generic companies typically report portfolios rather than individual product revenue.

The economic model is therefore volume-led:

Revenue driver	Direction
Hypertension prevalence	Positive
Fixed-dose adherence demand	Positive
Generic prescription volume	Positive
Average selling price	Negative
Number of approved suppliers	Negative
API and excipient costs	Variable
Pharmacy benefit reimbursement	Negative
Brand recognition	Limited after generic entry
Hospital and tender demand	Volume-positive, margin-negative

What generic entry risks exist for amlodipine and valsartan?

Generic launch risk is low for the category but remains relevant for individual manufacturers.

Supply and manufacturing risk

A supplier can lose share because of FDA warning letters, manufacturing observations, recalls, dissolution failures, contamination, or API shortages. Valsartan products have also faced historical supply-chain scrutiny because of nitrosamine contamination involving certain API manufacturers. That issue affected multiple valsartan products and demonstrated the importance of API traceability and supplier qualification (FDA, 2018).

Commercial risk

The principal commercial risks are:

• Rapid price erosion after additional ANDA approvals.
• Wholesaler concentration.
• Low or negative margins in rebate-heavy channels.
• Substitution by separate amlodipine and valsartan tablets.
• Switching to another ARB/CCB combination.
• Tender awards based primarily on price.
• Product discontinuation after manufacturing cost increases.

Regulatory risk

Generic manufacturers must maintain ANDA compliance, current labeling, pharmacovigilance systems, and product quality. A product can retain approval but become commercially unavailable if manufacturing capacity is withdrawn or a supplier exits the market.

Is there biosimilar risk for amlodipine and valsartan?

No. Biosimilar risk does not apply because amlodipine and valsartan are chemically synthesized small molecules, not biologics. The relevant competitive risk is generic substitution under the ANDA framework and equivalent national procedures outside the United States.

What licensing deals affect amlodipine and valsartan?

The principal historical commercial relationship was the Novartis development and commercialization of Exforge. The product was part of Novartis's broader cardiovascular portfolio, which included valsartan-based products and other antihypertensive combinations.

Current licensing value is limited. The product is mature, widely genericized, and generally unsuitable as a standalone asset for a high-value licensing transaction. Licensing opportunities may still arise around:

• Regional distribution rights.
• Private-label supply.
• Fixed-dose combination portfolios.
• Government procurement.
• Manufacturing and technology-transfer agreements.
• Emerging-market registration rights.

These arrangements are usually supply or commercialization agreements rather than transactions based on durable patent exclusivity.

What patent litigation affects amlodipine and valsartan?

Historical litigation risk centered on ANDA Paragraph IV challenges to Exforge patents. The principal issues would have included validity, infringement, patent listing scope, and the timing of generic approval.

Current litigation exposure is more likely to involve:

• Product liability.
• Manufacturing defects.
• Recall-related claims.
• API contamination.
• Contract disputes.
• Antitrust claims involving generic supply or distribution.
• Patent disputes over a specific formulation or process.

A broad patent litigation case is unlikely to restore exclusivity for the original immediate-release combination because the relevant market protection has already expired.

What are the geographic market dynamics?

The United States is a mature generic market with strong substitution and concentrated purchasing. Europe has extensive generic use but differs by country in reimbursement, reference pricing, physician prescribing, and pharmacy substitution.

Emerging markets can produce higher unit growth but lower pricing and more fragmented regulatory requirements. Commercial success depends on local registration, brand recognition, distributor relationships, and public procurement.

Region	Market characteristic
United States	High generic substitution, low unit pricing, concentrated channels
Western Europe	Reimbursement-driven, country-specific pricing and substitution
Central and Eastern Europe	Branded-generic competition remains important
India	Large volume, intense price competition, fragmented brands
Latin America	Mixed public and private channels, local registration barriers
Middle East and Africa	Tender-driven demand and distributor dependence

What are the likely generic launch scenarios?

The product is already in the post-launch generic phase in the United States. For a new manufacturer, the realistic scenarios are:

Low-cost commodity launch

The supplier enters with limited differentiation and competes on price. This strategy can generate volume but carries low margins and high dependence on contracts.

Supply-reliability strategy

The supplier emphasizes manufacturing redundancy, stable API sourcing, and consistent fill rates. This can support better contracting positions than a purely price-led launch.

Regional branded-generic strategy

The company markets the combination under a local brand, using physician recognition and pharmacy promotion. This approach is more viable in markets where branded generics retain prescribing influence.

Portfolio strategy

The company offers amlodipine/valsartan alongside valsartan/hydrochlorothiazide, amlodipine/olmesartan, and the individual components. Portfolio breadth improves contracting leverage and reduces dependence on one SKU.

Key Takeaways

• Amlodipine besylate and valsartan is a mature small-molecule combination with broad generic competition.
• Exforge, the original Novartis brand, no longer has meaningful broad-market exclusivity.
• The commercial market is driven by prescription volume, adherence benefits, and procurement access rather than patent protection.
• Biosimilar risk is irrelevant; ANDA-based generic substitution is the central competitive issue.
• Formulation and manufacturing patents may affect individual suppliers but do not create a durable market-wide barrier.
• Financial value has moved from branded revenue to low-margin generic volume.
• The main risks are price erosion, API quality, supply reliability, channel concentration, and therapeutic substitution.
• New entrants need a cost, supply, regional, or portfolio advantage to achieve attractive returns.

Frequently Asked Questions

Is amlodipine besylate and valsartan still a profitable pharmaceutical product?

It can be profitable at scale, but profitability is generally lower than during the Exforge branded period. Manufacturing efficiency, reliable supply, and contract access determine returns.

Is Exforge still protected by patents?

Broad commercial protection for the original combination has expired or become commercially ineffective. Narrow patents may require separate claim and jurisdiction review.

Can a generic manufacturer launch amlodipine and valsartan without patent litigation?

In the current mature market, ordinary generic entry is generally post-exclusivity. A new formulation, label, or jurisdiction-specific product may create separate patent issues.

Does valsartan contamination affect amlodipine and valsartan tablets?

It can affect products using contaminated valsartan API. The risk is supplier-specific and controlled through FDA testing, recalls, API qualification, and manufacturing oversight.

Which combination is cheaper: amlodipine and valsartan or the two individual drugs?

The answer depends on payer contracts, pharmacy pricing, country, dose, and generic supply. Separate tablets may be cheaper, while the fixed-dose combination can reduce pill burden and improve adherence.

References

1. U.S. Food and Drug Administration. (2007). Exforge prescribing information.
2. U.S. Food and Drug Administration. (2018). FDA updates and press announcements on NDMA in valsartan products.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. Novartis AG. (2007-2015). Annual reports and financial statements.
5. United States Patent and Trademark Office. (2002). U.S. Patent No. 6,485,745: Pharmaceutical compositions containing valsartan and amlodipine.
6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.